Verified Clinical Trials uses fingerprint biometrics to combat duplicate enrollment
Verified Clinical Trials continues to enhance their offerings and has successfully and seamlessly offered the newest technology that includes a biometrics fingerprint platform to their clients and the research community. The newest technology will improve accuracy while improving efficiencies at the site level where verifications are performed.
The largest and most comprehensive research subject clinical trials database registry has delivered new technology and offerings. The entire package has enabled the Verified Clinical Trials network to expand its footprint in the research world even further.
Duplicate enrollment in clinical trials is an ongoing problem in the clinical trials industry that continues to plague the safety and data of clinical trials. Prior to Verified Clinical Trials there was no clear cut solution to this dilemma. With the advent of the Verified Clinical Trials clinical trials research subject database registry there now exists a solution to the issue. Verified Clinical Trials has been recognized and endorsed by many of the largest and most significant clinical trials companies worldwide. Government agencies have chosen to utilize Verified Clinical Trials to protect their clinical trials too.
Verified Clinical Trials is a HIPAA compliant secure system that complies with 21 CFR part 11 as well. Verified Clinical Trials uses only partial identifiers and the actual fingerprint image image is not stored.
Mitchell Efros, M.D., FACS president/CEO, said, “Adding fingerprint biometrics to prevent dual enrollment in clinical trials has improved the product and service that we offer to our clients and ultimately to the worldwide consumer that relies upon safe and effective drug development. There are also several new developments in the Verified Clinical Trials system that improve the end user experience."
Kerri Weingard, ANP, chief operating officer, said, "Fortunately, recognizing and preventing duplicate enrollment in clinical trials and stopping professional research subjects has decidedly improved over the past few years. The issue is real and now more than ever is the time to enlist the entire research community. With the addition of fingerprint biometrics to the Verified Clinical Trials arsenal this has helped realize this goal."
Weingard added, "Biometric functionality was added into VCT's services after high demand by many of our current phase I CPUs and CNS pharmaceutical companies to reduce the concern and issue of potential fake identification. Falsified identification is a significant problem that is resolved with fingerprint biometrics. With VCT's past IDmetric functionality and added biometric service, tracking of fake IDs and providing metrics behind the issue is addressed unlike any other company."